Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).
Current role